

# STANDARD MEDICARE PART B MANAGEMENT

## ILUMYA (tildrakizumab-asmn)

### POLICY

#### I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

##### FDA-Approved Indication

Ilumya is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy

All other indications will be assessed on an individual basis. Submissions for indications other than those enumerated in this policy should be accompanied by supporting evidence from Medicare approved compendia.

#### II. DOCUMENTATION

The following documentation must be available, upon request, for continuation of therapy:

Chart notes or medical record documentation of decreased body surface area (BSA) affected and/or improvement in signs and symptoms.

#### III. CRITERIA FOR INITIAL APPROVAL

##### **Moderate to severe plaque psoriasis**

Authorization of 12 months may be granted for the treatment of moderate to severe plaque psoriasis.

#### IV. CONTINUATION OF THERAPY

All members (including new members) requesting authorization for continuation of therapy must be currently receiving therapy with the requested agent.

Authorization for 12 months may be granted when all of the following criteria are met:

1. The member is currently receiving therapy with Ilumya
2. Ilumya is being used to treat an indication enumerated in Section II
3. The member has achieved or maintained a positive clinical response as evidenced by low disease activity or improvement in signs and symptoms of the condition when any of the following is met:
  - i. Reduction in body surface area (BSA) affected from baseline
  - ii. Improvement in signs and symptoms from baseline (e.g., itching, redness, flaking, scaling, burning, cracking, pain)

|                            |
|----------------------------|
| <b>Reference number(s)</b> |
| 4697-A                     |

## V. REFERENCES

1. Ilumya [package insert]. Cranbury, NJ: Sun Pharmaceutical Industries, Inc.; July 2020.
2. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 4: Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. *J Am Acad Dermatol*. 2009;61(3):451-485.
3. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 6: Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. *J Am Acad Dermatol*. 2011;65(1):137-174.
4. Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. *J Am Acad Dermatol*. 2019;80(4):1029-1072.
5. Menter A, Gelfand JM, Connor C, et al. Joint AAD-NPF guidelines of care for the management of psoriasis with systemic nonbiologic therapies. *J Am Acad Dermatol*. 2020;82(6):1445-1486.